Last checked at 
(Alliance News) - Angle PLC on Thursday said that "breakthrough results" from its latest blood sample cancer trials would allow it to expand its product sales and pharma services.
Shares in the Surrey-based medical diagnostics provider were up 71% at 22.60 each in London on Thursday morning.
This followed Angle's announcement that its DNA molecular analysis of cancer patient blood samples had yielded strong results for its Parstortix circulating tumour cell harvesting technology.
Actionable cancer mutations were identified in circulating tumour cell metastatic cancer cells that were not present in the ctDNA fragments from the same blood draw. The previously unidentified DNA variants were discovered in 70% of breast cancer patient samples, 70% of lung cancer samples and 60% of ovarian cancer samples.
Additionally, Angle said that the variants included those targeted by "widely used FDA approved drugs".
The group believes that a combined molecular profiling of both CTC and ctDNA samples has the potential "to revolutionise the way cancer is treated".
Angle said that this would allow oncologists to track patients' cancer's evolution, inform treatment decisions, monitor treatment responses and highlight drug-resistant mechanisms.
This will "focus healthcare expenditure" for patients, by giving insight into the most suitable therapy choices, while maximising the potential for successful treatment, Angle added.
Angle said that it will use these results to support the offer of sample-to-answer solutions to pharmaceutical services customers using the unique combined analysis.
Angle also aims to expedite clinical adoption by working with clinicians and opinion leaders in establishing further clinical studies to build upon the recent dataset.
Angle's Chief scientific officer Dr Karen Miller said: "We are particularly excited about finding such high levels of additional variants in the CTCs that are not present in ctDNA, as this provides potentially additional information for the clinicians on which to base their treatment options".
By Hugh Cameron, Alliance News reporter
Comments and questions to newsroom@alliancenews.com
Copyright 2023 Alliance News Ltd. All Rights Reserved.
